BioSpace News Archive

Werewolf Therapeutics, Inc. announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Candel Therapeutics, Inc. announced the Company will present a poster presentation at the American Association for Cancer Research Annual Meeting taking place April 5-10, 2024, in San Diego, CA.

Quanta Therapeutics announced it will give a late-breaking poster presentation of QTX3544 at the American Association for Cancer Research Annual Meeting being held April 5-10, 2024, in San Diego, California.

Hummingbird Bioscience announced two upcoming poster presentations at the American Association for Cancer Research Meeting 2024 in San Diego, California.

Gilead Sciences, Inc. announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.

Tubulis announced that two abstracts with comprehensive preclinical data on their next-generation antibody-drug conjugate candidates TUB-030 and TUB-040, have been accepted for poster presentations at the Annual Meeting of the American Association for Cancer Research, taking place April 5-10, 2024 in San Diego.

Bicycle Therapeutics plc announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego on April 5-10.

Nuvalent, Inc. (Nasdaq: NUVL) today announced upcoming preclinical data poster presentations further characterizing the preclinical profiles of its novel HER2-selective inhibitor, NVL-330, and novel ROS1-selective inhibitor, zidesamtinib (NVL-520), at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5 – 10 in San Diego.

Medtronic plc, a global leader in healthcare technology, announced it will participate in the 26th annual Barclays global healthcare conference on Tuesday, March 12, 2024.

Flare Therapeutics Inc. announced a poster presentation identifying immunosuppressive programming associated with high PPARG expression in urothelial cancer patients treated with anti-PD1 therapy at the upcoming American Association for Cancer Research Annual Meeting 2024 taking place April 5-10 in San Diego, California.